Miloš Žarković

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

George J. Kahaly, Michaela Riedl, J. König et al. · The Lancet Diabetes & Endocrinology · 2018 · 216 citations

Pharmacy, Endocrinology, Pharmacotherapy +9

Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine

M Doknic, Sandra Pekić, Miloš Žarković et al. · European Journal of Endocrinology · 2002 · 172 citations

Medicine, Endocrinology, Pharmacology +14

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement

Petros Perros, László Hegedüs, Luigi Bartalena et al. · Orphanet Journal of Rare Diseases · 2017 · 170 citations · Full text

Medicine, Dermatology, Endocrinology +6

PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012

Petros Perros, Miloš Žarković, Claudio Azzolini et al. · British Journal of Ophthalmology · 2015 · 119 citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism

Wilmar M. Wiersinga, Miloš Žarković, Luigi Bartalena et al. · European Journal of Endocrinology · 2018 · 93 citations · Full text

Medicine, Endocrinology, Clinical Epidemiology +13